round button
Leave a message

North America Stem Cell Therapy Market – Industry Trends and Forecast to 2029

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

North America Stem Cell Therapy Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Published Report
  • Jun 2022
  • North America
  • 350 Pages
  • No of Tables: 48
  • No of Figures: 42

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE NORTH AMERICA STEM CELL THERAPY MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 NORTH AMERICA STEM CELL THERAPY MARKET: SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT SEGMENT LIFELINE CURVE

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 MARKET END USER COVERAGE GRID

2.11 SECONDARY SOURCES

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL

4.2 PORTER'S FIVE FORCES MODEL

5 EPIDEMIOLOGY

6 PIPELINE ANALYSIS FOR THE NORTH AMERICA STEM CELL THERAPY MARKET

7 NORTH AMERICA STEM CELL THERAPY MARKET: REGULATIONS

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 THE RISE IN PREVALENCE AND INCIDENCE OF CHRONIC DISEASES

8.1.2 RISE IN INVESTMENT IN RESEARCH AND DEVELOPMENT AND AVAILABILITY OF FUNDING FOR STEM CELL RESEARCH

8.1.3 GROWING BIOTECHNOLOGY SECTOR

8.1.4 RISE IN GMP CERTIFICATION APPROVALS FOR CELL THERAPY PRODUCTION FACILITIES

8.1.5 RISE IN CLINICAL TRIALS FOR STEM-CELL-BASED THERAPIES

8.2 RESTRAINTS

8.2.1 THE RISE IN COST OF STEM-CELL-BASED THERAPY RESEARCH

8.2.2 THE RISKS FACED WHILE UNDERGOING STEM CELL THERAPY

8.2.3 ETHICAL CONCERNS RELATED TO STEM CELL THERAPY RESEARCH

8.2.4 AVAILABILITY OF ALTERNATIVES

8.3 OPPORTUNITIES

8.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS

8.3.2 RISE IN HEALTHCARE EXPENDITURE

8.3.3 THE EMERGENCE OF INDUCED PLURIPOTENT STEM CELLS (IPSCS)

8.4 CHALLENGES

8.4.1 THE LACK OF SKILLED PROFESSIONALS REQUIRED FOR STEM CELL THERAPY

8.4.2 STRINGENT REGULATIONS

9 NORTH AMERICA STEM CELL THERAPY MARKET, BY PRODUCT TYPE

9.1 OVERVIEW

9.2 BONE MARROW DERIVED MESENCHYMAL STEM CELLS

9.3 PLACENTAL/UMBILICAL STEM CELL

9.4 ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELLS

9.5 OTHERS

10 NORTH AMERICA STEM CELL THERAPY MARKET, BY TYPE

10.1 OVERVIEW

10.2 ALLOGENEIC STEM CELL THERAPY

10.2.1 MUSCULOSKELETAL DISORDERS

10.2.2 WOUNDS AND INJURIES

10.2.3 ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)

10.2.4 SURGERIES

10.2.5 GASTROINTESTINAL DISEASES

10.2.6 OTHER APPLICATION

10.3 AUTOLOGOUS STEM CELL THERAPY

10.3.1 CARDIOVASCULAR DISEASES

10.3.2 GASTROINTESTINAL DISEASES

10.3.3 OTHER APPLICATION

11 NORTH AMERICA STEM CELL THERAPY MARKET, BY APPLICATION

11.1 OVERVIEW

11.2 MUSCULOSKELETAL DISORDERS

11.3 WOUNDS AND INJURIES

11.4 ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)

11.5 SURGERIES

11.6 GASTROINTESTINAL DISEASES

11.7 CARDIOVASCULAR DISEASES

11.8 OTHER APPLICATION

12 NORTH AMERICA STEM CELL THERAPY MARKET, BY END USER

12.1 OVERVIEW

12.2 HOSPITAL AND SURGICAL CENTERS

12.3 THERAPEUTIC COMPANIES

12.4 SERVICES COMPANIES

12.5 OTHERS

13 NORTH AMERICA STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL

13.1 OVERVIEW

13.2 DIRECT TENDER

13.3 THIRD PARTY DISTRIBUTORS

14 NORTH AMERICA STEM CELL THERAPY MARKET, BY REGION

14.1 NORTH AMERICA

14.1.1 U.S.

14.1.2 CANADA

15 NORTH AMERICA STEM CELL THERAPY MARKET: COMPANY LANDSCAPE

15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

16 SWOT ANALYSIS

17 COMPANY PROFILE

17.1 OSIRIS THERAPEUTICS, INC. (A SUBSIDIARY OF SMITH+NEPHEW) (2021)

17.1.1 COMPANY SNAPSHOT

17.1.2 REVENUE ANALYSIS

17.1.3 COMPANY SHARE ANALYSIS

17.1.4 PRODUCT PORTFOLIO

17.1.5 RECENT DEVELOPMENT

17.2 JCR PHARMACEUTICALS CO., LTD ( (2021)

17.2.1 COMPANY SNAPSHOT

17.2.2 REVENUE ANALYSIS

17.2.3 COMPANY SHARE ANALYSIS

17.2.4 PRODUCT PORTFOLIO

17.2.5 RECENT DEVELOPMENTS

17.3 ORTHOFIX MEDICAL INC. (2021)

17.3.1 COMPANY SNAPSHOT

17.3.2 REVENUE ANALYSIS

17.3.3 COMPANY SHARE ANALYSIS

17.3.4 PRODUCT PORTFOLIO

17.3.5 RECENT DEVELOPMENTS

17.4 MEDIPOST (2021)

17.4.1 COMPANY SNAPSHOT

17.4.2 REVENUE ANALYSIS

17.4.3 COMPANY SHARE ANALYSIS

17.4.4 PRODUCT PORTFOLIO

17.4.5 RECENT DEVELOPMENTS

17.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED (2021)

17.5.1 COMPANY SNAPSHOT

17.5.2 REVENUE ANALYSIS

17.5.3 COMPANY SHARE ANALYSIS

17.5.4 PRODUCT PORTFOLIO

17.5.5 RECENT DEVELOPMENT

17.6 CORESTEM, INC. (2021)

17.6.1 COMPANY SNAPSHOT

17.6.2 REVENUE ANALYSIS

17.6.3 PRODUCT PORTFOLIO

17.6.4 RECENT DEVELOPMENT

17.7 PHARMICELL CO., LTD. (2021)

17.7.1 COMPANY SNAPSHOT

17.7.2 PRODUCT PORTFOLIO

17.7.3 RECENT DEVELOPMENTS

17.8 ANTEROGEN.CO., LTD (2021)

17.8.1 COMPANY SNAPSHOT

17.8.2 PRODUCT PORTFOLIO

17.8.3 RECENT DEVELOPMENTS

17.9 ATHERSYS, INC.(2021)

17.9.1 COMPANY SNAPSHOT

17.9.2 REVENUE ANALYSIS

17.9.3 PRODUCT PORTFOLIO

17.9.4 RECENT DEVELOPMENTS

17.1 BRAINSTORM CELL LIMITED (2021)

17.10.1 COMPANY SNAPSHOT

17.10.2 PRODUCT PORTFOLIO

17.10.3 RECENT DEVELOPMENTS

17.11 BIORESTORATIVE THERAPIES, INC. (2021)

17.11.1 COMPANY SNAPSHOT

17.11.2 REVENUE ANALYSIS

17.11.3 PRODUCT PORTFOLIO

17.11.4 RECENT DEVELOPMENTS

17.12 HOLOSTEM TERAPIE AVANZATE S.R.L. (2021)

17.12.1 COMPANY SNAPSHOT

17.12.2 PRODUCT PORTFOLIO

17.12.3 RECENT DEVELOPMENTS

17.13 INTERNATIONAL STEMCELL CORPORATION (2021)

17.13.1 COMPANY SNAPSHOT

17.13.2 REVENUE ANALYSIS

17.13.3 PRODUCT PORTFOLIO

17.13.4 RECENT DEVELOPMENT

17.14 MESOBLAST LTD (2021)

17.14.1 COMPANY SNAPSHOT

17.14.2 REVENUE ANALYSIS

17.14.3 PRODUCT PORTFOLIO

17.14.4 RECENT DEVELOPMENTS

17.15 PLURISTEM INC.(2021)

17.15.1 COMPANY SNAPSHOT

17.15.2 REVENUE ANALYSIS

17.15.3 PRODUCT PORTFOLIO

17.15.4 RECENT DEVELOPMENT

17.16 STEMPEUTICS RESEARCH PVT LTD

17.16.1 COMPANY SNAPSHOT

17.16.2 PRODUCT PORTFOLIO

17.16.3 RECENT DEVELOPMENTS

17.17 U.S. STEM CELL, INC. (2021)

17.17.1 COMPANY SNAPSHOT

17.17.2 REVENUE ANALYSIS

17.17.3 PRODUCT PORTFOLIO

17.17.4 RECENT DEVELOPMENT

18 QUESTIONNAIRE

19 RELATED REPORTS

List of Table

TABLE 1 NORTH AMERICA STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 2 NORTH AMERICA BONE MARROW DERIVED MESENCHYMAL STEM CELLS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 3 NORTH AMERICA PLACENTAL/UMBILICAL STEM CELL IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 NORTH AMERICA ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELLS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 NORTH AMERICA OTHERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 NORTH AMERICA STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 7 NORTH AMERICA ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 NORTH AMERICA ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 9 NORTH AMERICA AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 NORTH AMERICA AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 11 NORTH AMERICA STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 12 NORTH AMERICA MUSCULOSKELETAL DISORDERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 NORTH AMERICA WOUNDS AND INJURIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 NORTH AMERICA ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 NORTH AMERICA SURGERIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 NORTH AMERICA GASTROINTESTINAL DISEASES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 NORTH AMERICA CARDIOVASCULAR DISEASES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 NORTH AMERICA OTHER APPLICATION IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 NORTH AMERICA STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 20 NORTH AMERICA HOSPITAL AND SURGICAL CENTERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 NORTH AMERICA THERAPEUTIC COMPANIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 NORTH AMERICA SERVICES COMPANIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 NORTH AMERICA OTHERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 NORTH AMERICA STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 25 NORTH AMERICA DIRECT TENDER IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 NORTH AMERICA THIRD PARTY DISTRIBUTORS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 NORTH AMERICA STEM CELL THERAPY MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 28 NORTH AMERICA STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 29 NORTH AMERICA STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 30 NORTH AMERICA ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 31 NORTH AMERICA AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 32 NORTH AMERICA STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)

TABLE 33 NORTH AMERICA STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 34 NORTH AMERICA STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 35 U.S. STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 36 U.S. STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 37 U.S. ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 38 U.S. AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 39 U.S. STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)

TABLE 40 U.S. STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 41 U.S. STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 42 CANADA STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 43 CANADA STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 44 CANADA ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 45 CANADA AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 46 CANADA STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)

TABLE 47 CANADA STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 48 CANADA STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

List of Figure

FIGURE 1 NORTH AMERICA STEM CELL THERAPY MARKET : SEGMENTATION

FIGURE 2 NORTH AMERICA STEM CELL THERAPY MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA STEM CELL THERAPY MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA STEM CELL THERAPY MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA STEM CELL THERAPY MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA STEM CELL THERAPY MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA STEM CELL THERAPY MARKET: DBMR POSITION GRID

FIGURE 8 NORTH AMERICA STEM CELL THERAPY MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 NORTH AMERICA STEM CELL THERAPY MARKET: END USER COVERAGE GRID

FIGURE 10 NORTH AMERICA STEM CELL THERAPY MARKET: SEGMENTATION

FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE NORTH AMERICA STEM CELL THERAPY MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 INCREASED INCIDENCE OF CHRONIC DISEASES, RISE IN CLINICAL TRIALS, GMP CERTIFICATION AND PRODUCT APPPROVALS IS EXPECTED TO DRIVE THE NORTH AMERICA STEM CELL THERAPY MARKET FROM 2022 TO 2029

FIGURE 13 PRODUCT TYPE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE NORTH AMERICA STEM CELL THERAPY MARKET FROM 2022 & 2029

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA STEM CELL THERAPY MARKET

FIGURE 15 NUMBER AND AGES OF PEOPLE 65 OR OLDER WITH ALZHEIMER'S DEMENTIA IN 2022

FIGURE 16 INCIDENCE OF VARIOUS TYPES OF CANCER IN 2020

FIGURE 17 NORTH AMERICA STEM CELL THERAPY MARKET: BY PRODUCT TYPE, 2021

FIGURE 18 NORTH AMERICA STEM CELL THERAPY MARKET: BY PRODUCT TYPE, 2022-2029 (USD MILLION)

FIGURE 19 NORTH AMERICA STEM CELL THERAPY MARKET: BY PRODUCT TYPE, CAGR (2022-2029)

FIGURE 20 NORTH AMERICA STEM CELL THERAPY MARKET: BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 21 NORTH AMERICA STEM CELL THERAPY MARKET: BY TYPE, 2021

FIGURE 22 NORTH AMERICA STEM CELL THERAPY MARKET: BY TYPE, 2022-2029 (USD MILLION)

FIGURE 23 NORTH AMERICA STEM CELL THERAPY MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 24 NORTH AMERICA STEM CELL THERAPY MARKET: BY TYPE, LIFELINE CURVE

FIGURE 25 NORTH AMERICA STEM CELL THERAPY MARKET: BY APPLICATION, 2021

FIGURE 26 NORTH AMERICA STEM CELL THERAPY MARKET: BY APPLICATION, 2022-2029 (USD MILLION)

FIGURE 27 NORTH AMERICA STEM CELL THERAPY MARKET: BY APPLICATION, CAGR (2022-2029)

FIGURE 28 NORTH AMERICA STEM CELL THERAPY MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 29 NORTH AMERICA STEM CELL THERAPY MARKET: BY END USER, 2021

FIGURE 30 NORTH AMERICA STEM CELL THERAPY MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 31 NORTH AMERICA STEM CELL THERAPY MARKET: BY END USER, CAGR (2022-2029)

FIGURE 32 NORTH AMERICA STEM CELL THERAPY MARKET: BY END USER, LIFELINE CURVE

FIGURE 33 NORTH AMERICA STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 34 NORTH AMERICA STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 35 NORTH AMERICA STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 36 NORTH AMERICA STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 37 NORTH AMERICA STEM CELL THERAPY MARKET: SNAPSHOT (2021)

FIGURE 38 NORTH AMERICA STEM CELL THERAPY MARKET: BY COUNTRY (2021)

FIGURE 39 NORTH AMERICA STEM CELL THERAPY MARKET: BY COUNTRY (2022 & 2029)

FIGURE 40 NORTH AMERICA STEM CELL THERAPY MARKET: BY COUNTRY (2021 & 2029)

FIGURE 41 NORTH AMERICA STEM CELL THERAPY MARKET: BY PRODUCT TYPE (2022-2029)

FIGURE 42 NORTH AMERICA STEM CELL THERAPY MARKET: COMPANY SHARE 2021 (%)

Frequently Asked Questions

The North America Stem Cell Therapy Market size will be worth USD 196.91 million by 2029.
The North America Stem Cell Therapy Market growth rate will be 8.6% by 2029.
The Rise in prevalence and incidence of chronic diseases is the growth driver of the North America Stem Cell Therapy Market.
The product type, type, application, end-user, and distribution channel are the factors on which the North America Stem Cell Therapy Market research is based.
The major companies in the North America Stem Cell Therapy Market are Osiris Therapeutics, Inc. (A subsidiary of Smith+Nephew), Orthofix Medical Inc., Takeda Pharmaceutical Company Limited, U.S. Stem Cell, Inc., BrainStorm Cell Limited, International Stemcell Corporation, Athersys, Inc., BioRestorative Therapies, Inc., JCR Pharmaceuticals Co., Ltd, ANTEROGEN.CO., LTD, MEDIPOST, Mesoblast Ltd, PHARMICELL Co., Ltd., STEMPEUTICS RESEARCH PVT LTD
a